### DRUG DISCOVERY AND DEVELOPMENT SOLUTIONS LTD. Balance Sheet

As at 31st Mar	Notes No	2014	2014	2013	2013
	•	USD	INR (' In Thousands)	USD	INR (' In Thousands)
I. EQUITY AND LIABILITIES					
Shareholders' Funds					
Share capital		~ccs:=cc;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;		wykajtoje od od odroko kajto od jiho od o	ere konstrueren erregis perse 🗖 des
Reserves & surplus	2	7,083,530	424,374	-	-
		7,083,531	424,374	-	•
Current liabilities	ka tibili tiba sa salipuja sa ngalipuja baha dipaga Jamana Bandipus tabagan g				
Trade payables	3	3,993	239	-	-
		3,993	239	+	-
	Total				
		7,087,524	424,614	-	-
II. ASSETS					
Non-current investments	4	7,087,523	424,614	-	-
		7,087,523	424,614	-	-
Current assets					
Short-term loans and advances	5	1	0		
		1	0		
	Total	7,087,524	424,614		

Rajneesh Gupta Head Accounts Place: Noida

Place : Noida Date : 22nd May 2014

## DRUG DISCOVERY AND DEVELOPMENT SOLUTIONS LTD. Statement of Profit and Loss

For the year ended 31st March,		Notes No	2014	2014	2013	2013
			USD	INR (' In Thousands)	USD	INR (' In
						Thousands)
		·			,	
EXPENSES			·		:	
Other expenses		6,	3,993	247	an taka kilosia balahatata bahasa Afrika an	aga kalang at tidang
Total expenses			3,993	247	-	-
Profit for the Year			(3,993)	(247)	-	-

Rajneesh Gupta Head Accounts Place : Noida Date : 22nd May 2014

### **Drug Discovery and Development Solutions Limited, Singapore**

CASH FLOW STATEMENT

For the year ended 31st March,		2014	2014
		USD	INR (' In Thousands)
A. Cash flows from operating activities			
Net income before minority interest		(3,993)	(247)
Operating profit before working capital chan	ges	(3,993)	(247)
	Polytical programs in the distribution and the control of the cont	en tres pe directo del Carpas pares apolis diaries pedicamen estas depositación. La compositación de la composit	
Adjustments for:	didipidyh kini suu ya ki kisidapuk kisimbah mani kisisso ongokami hisioko y kimmbi kitus isimbi kingoman.	etine atamaina ka maratata ana atamaina a	dia mangana mangangan katalan kanangan kanangan kanangan kanangan kanangan kanangan kanangan kanangan kanangan
(Increase)/Decrease in trade and other receivables		(1)	(0)
Increase/(Decrease) in trade and other payables		3,993	241
		(1)	(5)
Net cash inflow/(outflow) in course of opera	ting activities	(1)	(5)
B. Cash flow arising from financing activities:			
Proceeds from issue of share capital(including share pr	emium & net of share issue expenses)	1	0
Net cash inflow/(outflow) in course of financing activ	ities	1	0
C. Foreign currency translation difference arising on c	onsolidation		.5
Net Increase in cash & cash equivalents (A+B+C)			-
Cash & cash aguital ant at the along of the security live	No. Carlone in dividend accounts		
Cash & cash equivalents at the close of the year(includ	ing parance in dividend accounts)		-

Notes:

1) Cash Flow Statement has been prepared under the indirect method as set out in the Accounting Standard 3 (AS-3)-" Cash Flow Statements".

Rajneesh Gupta Head Accounts Place: Noida

Date: 22nd May, 2014

#### DRUG DISCOVERY AND DEVELOPMENT SOLUTIONS LTD.

Notes to the Financial Statements

As at 31st Mar	2014	2014	2013	2013
Particulars	USD	INR (' In Thousands)	USD	INR (' In Thousands)
1. SHARE CAPITAL Authorized				
Equity Share Capital Preference share capital	Analysis and Analy			
Issued & Subscribed 1 equity shares of USD 1 each	-			-
Paid up 1 equity shares of USD 1 each	1	0		

- 1) The Company has only one class of shares referred to as equity shares having no par value. Each holder of equity shares is entitled to one vote per share.
- 2) In the event of liquidation of the Company, the holders of equity shares will be entitled to receive any of the remaining assets of the Company, after distribution of all preferential
- 3) The details of shareholders holding more than 5% shares in the company:

As at 31st Mar	2014	2014	2013	2013
Name of the shareholder	No of shares	% held	No of shares	% held
Jubilant Life Sciences Ltd, India -Holding company	1	100%	-	0%

4) The reconcilations of number of shares outstanding at beginning and at the end of reporting period

As at 31st Mar	2014	2014	2013	2013
	No	INR (' In Thousands)	\$ 1987 - 48	INR (' In
		·		Thousands)
Numbers of shares at the beginning	- 10 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	-		-
Add: 5hares issued during the year	1	0	v	_
Numbers of shares at the end	1	0		-

5) Shares held by holding company/ultimate holding company and/or their subsidiaries/associates

Out of the equity Shares issued by the company, shares held by it's holding company/ultimate holding company and/or their subsidiaries/associates are as below:

			1 2 4 5 5 5 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6	
As at 31st Mar	2014	2014	2013	2013
Name of the shareholder	No	INR (' In Thousands)		INR (' In
Jubilant Life Sciences Ltd, India-Holding company				Thousands)
1 equity shares of USD 1 each	1	0	-	

# DRUG DISCOVERY AND DEVELOPMENT SOLUTIONS LTD. Notes to the Financial Statements

As at 31st Mar	2014	2014	2013	2013
	USD	INR (' In Thousands)	USD	INR (' In Thousands)
2. RESERVES AND SURPLUS				
Capital Reserve		-		
As per last Balance Sheet				
Additions/Consequent of acquisition	7,087,523	437,655	-	-
	7,087,523	437,655	-	-
Foreign Currency Translation Reserve	and and the state of a constant of the first open for	valudarini kali kulin karif fantylid kulingurjulguk	i kanpilandiya di kabasa di pak di Girandiya da tah di haziya d	
Foreign Currency Translation Reserve During the Year	-	(13,034)	-	-
Policipal currency Transmitted News Control of the Control	-	(13,034)	-	-
Surplus as per P&L Account				
As per last Balance Sheet				
Add: Net Profit after tax transferred from Statement of Profit and Loss	(3,993)	(247)	-	-
	(3,993)	(247)	-	-
	7,083,530	424,374	-	-
3. TRADE PAYABLES				
Trade payables-others	3,993	239	-	-
Trade paragraphs	3,993	239	-	-
	1995 (10,000)			
4. NON-CURRENT INVESTMENTS				
Investment in Subsidiary/ Fellow subsidiaries Companies		-		
JUBILANT LIFE SCIENCES (BVI) LTD				
3,972,501 equity shares of USD 1 each JUBILANT INNOVATION (BVI) LTD	3,952,898	236,818		
16,2S5,000 equity shares of USD 1 each	3,134,625	187,795		
	7,087,523	424,614	-	-
5. SHORT TERM LOANS AND ADVANCES				
- Advance recoverable in cash & kind				
- From related parties	1	0	-	-
	1	0		
6. OTHER EXPENSE		A Committee		
Legal, professional & consultancy charges	3,993	247	-	-
zaber 1 k. arasarara zanakuranal anarbas	3,993	247	-	-